GLAXOSMITHKLINE PLC Form 6-K October 10, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending October 2013

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

_

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of the following increases in interests in American Depositary Shares (ADSs) of GlaxoSmithKline plc purchased at a price of \$50.2130 per ADS on 3 October 2013, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 3 October 2013.

Director/PDMR	Number of ADSs	Connected Person	Number of ADSs
Dr M M Slaoui	932.851	Dr K Slaoui	15.618
Mrs D P Connelly	484.041	-	-
Mr W C Louv	84.312	-	-
Mr D E Troy	284.755	-	-

The Company was advised of this information on 9 October 2013.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).

S M Bicknell Company Secretary

10 October 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: October 10, 2013

By: SIMON BICKNELL

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Simon Bicknell Authorised Signatory for and on behalf of GlaxoSmithKline plc